{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:33Z","timestamp":1788581553750,"version":"build-2803163510"},"reference-count":83,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.1248\/bpb.b26-00318","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:18:35Z","timestamp":1788214715000},"page":"1334-1351","source":"Crossref","is-referenced-by-count":0,"title":["Multifaceted Food Effects on Intestinal Drug Uptake Transporters: Mechanistic Insights from Small Molecules to Macromolecules"],"prefix":"10.1248","volume":"49","author":[{"given":"Ikumi","family":"Tamai","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci.<\/i>, 51<\/b>, 1427\u20131437 (1992).","DOI":"10.1016\/0024-3205(92)90537-Y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol.<\/i>, 48<\/b>, 1083\u20131089 (1996).","DOI":"10.1111\/j.2042-7158.1996.tb05904.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Galetin A, Brouwer KLR, Tweedie D, et al.<\/i> Membrane transporters in drug development and as determinants of precision medicine. Nat. Rev. Drug Discov.<\/i>, 23<\/b>, 255\u2013280 (2024).","DOI":"10.1038\/s41573-023-00877-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hosomi A, Nakanishi T, Fujita T, Tamai I. Extra-renal elimination of uric acid via<\/i> intestinal efflux transporter BCRP\/ABCG2. PLoS One<\/i>, 7<\/b>, e30456 (2012).","DOI":"10.1371\/journal.pone.0030456"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tsuji A, Tamai I, Hirooka H, Terasaki T. Beta-lactam antibiotics and transport via<\/i> the dipeptide carrier system across the intestinal brush-border membrane. Biochem. Pharmacol.<\/i>, 36<\/b>, 565\u2013567 (1987).","DOI":"10.1016\/0006-2952(87)90369-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tamai I, Tomizawa N, Kadowaki A, Terasaki T, Nakayama K, Higashida H, Tsuji A. Functional expression of intestinal dipeptide\/beta-lactam antibiotic transporter in Xenopus laevis<\/i> oocytes. Biochem. Pharmacol.<\/i>, 48<\/b>, 881\u2013888 (1994).","DOI":"10.1016\/0006-2952(94)90358-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res.<\/i>, 13<\/b>, 963\u2013977 (1996).","DOI":"10.1023\/A:1016086003070"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nozawa T, Toyobuku H, Kobayashi D, Kuruma K, Tsuji A, Tamai I. Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. J. Pharm. Sci.<\/i>, 92<\/b>, 2208\u20132216 (2003).","DOI":"10.1002\/jps.10491"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tsuji A, Simanjuntak MT, Tamai I, Terasaki T. pH-dependent intestinal transport of monocarboxylic acids: carrier-mediated and H+<\/sup>-cotransport mechanism versus<\/i> pH-partition hypothesis. J. Pharm. Sci.<\/i>, 79<\/b>, 1123\u20131124 (1990).","DOI":"10.1002\/jps.2600791217"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm. Res.<\/i>, 12<\/b>, 1727\u20131732 (1995).","DOI":"10.1023\/A:1016269806840"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A. Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem. Biophys. Res. Commun.<\/i>, 214<\/b>, 482\u2013489 (1995).","DOI":"10.1006\/bbrc.1995.2312"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tamai I. How should we handle decreased efficacy caused by DDI on transporters for drug absorption and target-tissue distribution, but not associated with toxicity? Drug Metab. Pharmacokinet.<\/i>, 28<\/b>, 451\u2013452 (2013).","DOI":"10.2133\/dmpk.DMPK-13-PF-906"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Nakanishi T, Tamai I. Interaction of drug or food with drug transporters in intestine and liver. Curr. Drug Metab.<\/i>, 16<\/b>, 753\u2013764 (2015).","DOI":"10.2174\/138920021609151201113537"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, Shek KY, Zuo Z, Lam TN. A review of food\u2013drug interactions on oral drug absorption. Drugs<\/i>, 77<\/b>, 1833\u20131855 (2017).","DOI":"10.1007\/s40265-017-0832-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Funai Y, Shirasaka Y, Ishihara M, Takemura M, Ichijo K, Kishimoto H, Inoue K. Effect of osmolality on the pharmacokinetic interaction between apple juice and atenolol in rats. Drug Metab. Dispos.<\/i>, 47<\/b>, 386\u2013391 (2019).","DOI":"10.1124\/dmd.118.084483"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet<\/i>, 337<\/b>, 268\u2013269 (1991).","DOI":"10.1016\/0140-6736(91)90872-M"},{"key":"17","unstructured":"17) Guo LQ, Yamazoe Y. Inhibition of cytochromes P450 by furanocoumarins in grapefruit juice and herbal medicine. Acta Pharmacol. Sin.<\/i>, 25<\/b>, 129\u2013136 (2004)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: Forbidden fruit or avoidable consequences? CMAJ<\/i>, 185<\/b>, 309\u2013316 (2013).","DOI":"10.1503\/cmaj.120951"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br. J. Clin. Pharmacol.<\/i>, 50<\/b>, 455\u2013463 (2000).","DOI":"10.1046\/j.1365-2125.2000.00283.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) D\u00fcrr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John\u2019s Wort induces intestinal P-glycoprotein\/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther.<\/i>, 68<\/b>, 598\u2013604 (2000).","DOI":"10.1067\/mcp.2000.112240"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John\u2019s wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab. Dispos.<\/i>, 33<\/b>, 547\u2013554 (2005).","DOI":"10.1124\/dmd.104.002485"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun.<\/i>, 273<\/b>, 251\u2013260 (2000).","DOI":"10.1006\/bbrc.2000.2922"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther.<\/i>, 71<\/b>, 11\u201320 (2002).","DOI":"10.1067\/mcp.2002.121152"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res.<\/i>, 18<\/b>, 1262\u20131269 (2001).","DOI":"10.1023\/A:1013077609227"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther.<\/i>, 302<\/b>, 804\u2013813 (2002).","DOI":"10.1124\/jpet.302.2.804"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther.<\/i>, 306<\/b>, 703\u2013708 (2003).","DOI":"10.1124\/jpet.103.051300"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther.<\/i>, 308<\/b>, 438\u2013445 (2004).","DOI":"10.1124\/jpet.103.060194"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kikuchi A, Nozawa T, Wakasawa T, Maeda T, Tamai I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab. Pharmacokinet.<\/i>, 21<\/b>, 308\u2013314 (2006).","DOI":"10.2133\/dmpk.21.308"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev.<\/i>, 64<\/b>, 508\u2013514 (2012).","DOI":"10.1016\/j.addr.2011.07.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab. Pharmacokinet.<\/i>, 27<\/b>, 106\u2013121 (2012).","DOI":"10.2133\/dmpk.DMPK-11-RV-099"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, Ohashi K. The effects of the SLCO2B1 c.1457C\u2009>\u2009T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet. Genomics<\/i>, 21<\/b>, 84\u201393 (2011).","DOI":"10.1097\/FPC.0b013e32834300cc"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. Role of Oatp2b1 in drug absorption and drug\u2013drug interactions. Drug Metab. Dispos.<\/i>, 48<\/b>, 419\u2013425 (2020).","DOI":"10.1124\/dmd.119.090316"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Medwid S, Li MMJ, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, Schwarz UI, Kim RB, Tirona RG. Fexofenadine and rosuvastatin pharmacokinetics in mice with targeted disruption of organic anion transporting polypeptide 2B1. Drug Metab. Dispos.<\/i>, 47<\/b>, 832\u2013842 (2019).","DOI":"10.1124\/dmd.119.087619"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Takemura M, Inoue K, Tamai I, Shirasaka Y. Magnitude of fruit juice-drug interactions due to osmolality-dependent fluid secretion: differences among apple, orange, and grapefruit juices. Biol. Pharm. Bull.<\/i>, 47<\/b>, 72\u201378 (2024).","DOI":"10.1248\/bpb.b23-00490"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Takemura M, Tanaka Y, Inoue K, Tamai I, Shirasaka Y. Influence of osmolality on gastrointestinal fluid volume and drug absorption: potential impact on oral salt supplementation. J. Pharm. Health Care Sci.<\/i>, 7<\/b>, 29 (2021).","DOI":"10.1186\/s40780-021-00212-z"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Zou L, Spanogiannopoulos P, Pieper LM, Chien HC, Cai W, Khuri N, Pottel J, Vora B, Ni Z, Tsakalozou E, Zhang W, Shoichet BK, Giacomini KM, Turnbaugh PJ. Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 117<\/b>, 16009\u201316018 (2020).","DOI":"10.1073\/pnas.1920483117"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Jang JH, Jeong SH, Lee YB. Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via<\/i> pharmacometrics. J. Pharm. Anal.<\/i>, 13<\/b>, 660\u2013672 (2023).","DOI":"10.1016\/j.jpha.2023.04.001"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gr\u00f6er C, Br\u00fcck S, Lai Y, Paulick A, Busemann A, Heidecke CD, Siegmund W, Oswald S. LC-MS\/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. J. Pharm. Biomed. Anal.<\/i>, 85<\/b>, 253\u2013261 (2013).","DOI":"10.1016\/j.jpba.2013.07.031"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Keiser M, Kaltheuner L, Wildberg C, M\u00fcller J, Grube M, Partecke LI, Heidecke CD, Oswald S. The organic anion-transporting peptide 2B1 is localized in the basolateral membrane of the human jejunum and Caco-2 monolayers. J. Pharm. Sci.<\/i>, 106<\/b>, 2657\u20132663 (2017).","DOI":"10.1016\/j.xphs.2017.04.001"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Shirasaka Y, Shichiri M, Mori T, Nakanishi T, Tamai I. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. J. Pharm. Sci.<\/i>, 102<\/b>, 3418\u20133426 (2013).","DOI":"10.1002\/jps.23653"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Shirasaka Y, Mori T, Shichiri M, Nakanishi T, Tamai I. Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites. Drug Metab. Pharmacokinet.<\/i>, 27<\/b>, 360\u2013364 (2012).","DOI":"10.2133\/dmpk.DMPK-11-SH-080"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Tamai I, Nakanishi T. OATP transporter-mediated drug absorption and interaction. Curr. Opin. Pharmacol.<\/i>, 13<\/b>, 859\u2013863 (2013).","DOI":"10.1016\/j.coph.2013.09.001"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharm. Res.<\/i>, 31<\/b>, 2035\u20132043 (2014).","DOI":"10.1007\/s11095-014-1305-7"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br. J. Clin. Pharmacol.<\/i>, 57<\/b>, 448\u2013455 (2004).","DOI":"10.1046\/j.1365-2125.2003.02030.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Hoshino Y, Fujita D, Nakanishi T, Tamai I. Molecular localization and characterization of multiple binding sites of organic anion transporting polypeptide 2B1 (OATP2B1) as the mechanism for substrate and modulator dependent drug\u2013drug interaction. MedChemComm<\/i>, 7<\/b>, 1775\u20131782 (2016).","DOI":"10.1039\/C6MD00235H"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Shirasaka Y, Shichiri M, Murata Y, Mori T, Nakanishi T, Tamai I. Long-lasting inhibitory effect of apple and orange juices, but not grapefruit juice, on OATP2B1-mediated drug absorption. Drug Metab. Dispos.<\/i>, 41<\/b>, 615\u2013621 (2013).","DOI":"10.1124\/dmd.112.049635"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) K\u00f6ck K, Koenen A, Giese B, Fraunholz M, May K, Siegmund W, Hammer E, V\u00f6lker U, Jedlitschky G, Kroemer HK, Grube M. Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1<\/i>) function by protein kinase C-mediated internalization. J. Biol. Chem.<\/i>, 285<\/b>, 11336\u201311347 (2010).","DOI":"10.1074\/jbc.M109.056457"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Di Paolo A, Bocci G, Polillo M, Del Re M, Di Desidero T, Lastella M, Danesi R. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr. Drug Metab.<\/i>, 12<\/b>, 932\u2013943 (2011).","DOI":"10.2174\/138920011798062283"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Takane H. Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications. Yakugaku Zasshi<\/i>, 131<\/b>, 1589\u20131594 (2011).","DOI":"10.1248\/yakushi.131.1589"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro<\/i> evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos.<\/i>, 33<\/b>, 434\u2013439 (2005).","DOI":"10.1124\/dmd.104.001909"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Fujita D, Saito Y, Nakanishi T, Tamai I. Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride. Drug Metab. Dispos.<\/i>, 44<\/b>, 1\u20137 (2016).","DOI":"10.1124\/dmd.115.066712"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res.<\/i>, 84<\/b>, 697\u2013702 (1993).","DOI":"10.1111\/j.1349-7006.1993.tb02031.x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res.<\/i>, 86<\/b>, 978\u2013984 (1995).","DOI":"10.1111\/j.1349-7006.1995.tb03010.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J. Clin. Oncol.<\/i>, 24<\/b>, 563\u2013570 (2006).","DOI":"10.1200\/JCO.2005.03.2847"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr. Blood Cancer<\/i>, 58<\/b>, 372\u2013379 (2012).","DOI":"10.1002\/pbc.23075"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm. Res.<\/i>, 31<\/b>, 204\u2013215 (2014).","DOI":"10.1007\/s11095-013-1153-x"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Liman ER, Tytgat J, Hess P. Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron<\/i>, 9<\/b>, 861\u2013871 (1992).","DOI":"10.1016\/0896-6273(92)90239-A"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Debont T, Daenens P, Tytgat J. An improved fractionation and fast screening method for the identification of new and selective neurotoxins. Neurosci. Res.<\/i>, 24<\/b>, 201\u2013206 (1996).","DOI":"10.1016\/0168-0102(95)00982-5"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Taheri H, de Bruijn P, Li Y, Kleinert NR, Corps KN, Mathijssen RHJ, Huang KM, Sparreboom A, Hu S. OATP2B1 deficiency ameliorates irinotecan-induced gastrointestinal toxicity. Clin. Transl. Sci.<\/i>, 19<\/b>, e70452 (2026).","DOI":"10.1111\/cts.70452"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Parvez MM, Basit A, Jariwala PB, G\u00e1borik Z, Kis E, Heyward S, Redinbo MR, Prasad B. Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation. Drug Metab. Dispos.<\/i>, 49<\/b>, 683\u2013693 (2021).","DOI":"10.1124\/dmd.121.000476"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Martha L, Nakata A, Furuya S, Liu W, Zhang X, Mizoi K, Ogihara T. Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept. Biochem. Biophys. Res. Commun.<\/i>, 665<\/b>, 19\u201325 (2023).","DOI":"10.1016\/j.bbrc.2023.04.109"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Huang D, Chen J, Zhao M, Shen H, Jin Q, Xiao D, Peng Z, Chen T, Zhang Y, Rao D, Liu M. Plant-derived extracellular vesicles: composition, function and clinical potential. J. Transl. Med.<\/i>, 23<\/b>, 1065 (2025).","DOI":"10.1186\/s12967-025-07101-1"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Davila B, He B. Extracellular vesicle-mediated RNA warfare: A cross-kingdom battleground. Curr. Opin. Plant Biol.<\/i>, 86<\/b>, 102741 (2025).","DOI":"10.1016\/j.pbi.2025.102741"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Fujita D, Arai T, Komori H, Shirasaki Y, Wakayama T, Nakanishi T, Tamai I. Apple-derived nanoparticles modulate expression of organic-anion-transporting polypeptide (OATP) 2B1 in Caco-2 cells. Mol. Pharm.<\/i>, 15<\/b>, 5772\u20135780 (2018).","DOI":"10.1021\/acs.molpharmaceut.8b00921"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) He Y, Cheng M, Yang R, Li H, Lu Z, Jin Y, Feng J, Tu L. Research progress on the mechanism of nanoparticles crossing the intestinal epithelial cell membrane. Pharmaceutics<\/i>, 15<\/b>, 1816 (2023).","DOI":"10.3390\/pharmaceutics15071816"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Arai M, Komori H, Fujita D, Tamai I. Uptake pathway of apple-derived nanoparticle by intestinal cells to deliver its cargo. Pharm. Res.<\/i>, 38<\/b>, 523\u2013530 (2021).","DOI":"10.1007\/s11095-021-03018-8"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Liu W, Nakano M, Nakanishi T, Nakajima M, Tamai I. Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24. Drug Metab. Pharmacokinet.<\/i>, 35<\/b>, 515\u2013521 (2020).","DOI":"10.1016\/j.dmpk.2020.07.007"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Komori H, Fujita D, Shirasaki Y, Zhu Q, Iwamoto Y, Nakanishi T, Nakajima M, Tamai I. MicroRNAs in apple-derived nanoparticles modulate intestinal expression of OATP2B1\/SLCO2B1<\/i> in humans. Drug Metab. Dispos.<\/i>, 49<\/b>, 803\u2013809 (2021).","DOI":"10.1124\/dmd.121.000380"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Nagasako-Akazome Y, Kanda T, Ohtake Y, Shimasaki H, Kobayashi T. Apple polyphenols influence cholesterol metabolism in healthy subjects with relatively high body mass index. J. Oleo Sci.<\/i>, 56<\/b>, 417\u2013428 (2007).","DOI":"10.5650\/jos.56.417"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Olivier A, Virgile D, Catherine B, Claudine M, Christine M, Christian R, Christian G, Sylvain G, Annick B. Apple pectin and a polyphenol-rich apple concentrate are more effective together than separately on cecal fermentations and plasma lipids in rats. J. Nutr.<\/i>, 133<\/b>, 1860\u20131865 (2003).","DOI":"10.1093\/jn\/133.6.1860"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Prpa EJ, Corpe CP, Atkinson B, Blackstone B, Leftley ES, Parekh P, Philo M, Kroon PA, Hall WL. Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial glucose concentrations following a high-carbohydrate meal: a randomized controlled trial in healthy adults and in vitro<\/i> studies. J. Nutr. Biochem.<\/i>, 85<\/b>, 108466 (2020).","DOI":"10.1016\/j.jnutbio.2020.108466"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Katsirma Z, Dimidi E, Rodriguez-Mateos A, Whelan K. Fruits and their impact on the gut microbiota, gut motility and constipation. Food Funct.<\/i>, 12<\/b>, 8850\u20138866 (2021).","DOI":"10.1039\/D1FO01125A"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Chedid V, Vijayvargiya P, Camilleri M. Elobixibat for the treatment of constipation. Expert Rev. Gastroenterol. Hepatol.<\/i>, 12<\/b>, 951\u2013960 (2018).","DOI":"10.1080\/17474124.2018.1522248"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ, Portincasa P. Bile acid physiology. Ann. Hepatol.<\/i>, 16<\/b>, s4\u2013s14 (2017).","DOI":"10.5604\/01.3001.0010.5493"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Zhu Q, Iwai R, Okaguchi T, Shirasaka Y, Tamai I. Apple juice relieves loperamide-induced constipation in rats by downregulating the intestinal apical sodium-dependent bile acid transporter ASBT. Food Funct.<\/i>, 14<\/b>, 4836\u20134846 (2023).","DOI":"10.1039\/D3FO00510K"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Usui S, Zhu Q, Komori H, Iwamoto Y, Nishiuchi T, Shirasaka Y, Tamai I. Apple-derived extracellular vesicles modulate the expression of human intestinal bile acid transporter ASBT\/SLC10A2 via<\/i> downregulation of transcription factor RAR\u03b1. Drug Metab. Pharmacokinet.<\/i>, 52<\/b>, 100512 (2023).","DOI":"10.1016\/j.dmpk.2023.100512"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Zhu Q, Komori H, Imamura R, Tamai I. A novel fluorescence-based method to evaluate ileal apical sodium-dependent bile acid transporter ASBT. J. Pharm. Sci.<\/i>, 110<\/b>, 1392\u20131400 (2021).","DOI":"10.1016\/j.xphs.2020.11.030"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Heidker RM, Caiozzi GC, Ricketts ML. Dietary procyanidins selectively modulate intestinal farnesoid X receptor-regulated gene expression to alter enterohepatic bile acid recirculation: elucidation of a novel mechanism to reduce triglyceridemia. Mol. Nutr. Food Res.<\/i>, 60<\/b>, 727\u2013736 (2016).","DOI":"10.1002\/mnfr.201500795"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Kr\u00fcger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res.<\/i>, 34<\/b> (Web Server), W451\u2013454 (2006).","DOI":"10.1093\/nar\/gkl243"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Husseini Z, Gilbert C. Milk-derived extracellular vesicles and microRNAs: potential modulators of intestinal homeostasis. FASEB J.<\/i>, 39<\/b>, e70947 (2025).","DOI":"10.1096\/fj.202501630R"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Munir J, Ngu A, Wang H, Ramirez DMO, Zempleni J. Review: Milk small extracellular vesicles for use in the delivery of therapeutics. Pharm. Res.<\/i>, 40<\/b>, 909\u2013915 (2023).","DOI":"10.1007\/s11095-022-03404-w"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Nishikawa M, Kusamori K, Itakura S. Development of plant-derived extracellular vesicle-based therapeutic systems. Yakugaku Zasshi<\/i>, 146<\/b>, 415\u2013421 (2026).","DOI":"10.1248\/yakushi.25-00171-3"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Chan SY, Snow JW. Formidable challenges to the notion of biologically important roles for dietary small RNAs in ingesting mammals. Genes Nutr.<\/i>, 12<\/b>, 13 (2017).","DOI":"10.1186\/s12263-017-0561-7"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00318\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:28:03Z","timestamp":1788578883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00318\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00318","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"b26-00318"}}